APA (7th ed.) Citation

YH, H., FT, L., CL, W., ZJ, W., YQ, L., HY, C., . . . SL, X. (2025). Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: A propensity score-matched analysis. Leukemia & lymphoma, 66(14), 2741. https://doi.org/10.1080/10428194.2025.2566317

Chicago Style (17th ed.) Citation

YH, Huang, et al. "Venetoclax Plus Hypomethylating Agents Versus Priming Regimen as the First-line Therapy for Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-related Changes: A Propensity Score-matched Analysis." Leukemia & Lymphoma 66, no. 14 (2025): 2741. https://doi.org/10.1080/10428194.2025.2566317.

MLA (9th ed.) Citation

YH, Huang, et al. "Venetoclax Plus Hypomethylating Agents Versus Priming Regimen as the First-line Therapy for Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-related Changes: A Propensity Score-matched Analysis." Leukemia & Lymphoma, vol. 66, no. 14, 2025, p. 2741, https://doi.org/10.1080/10428194.2025.2566317.